Oxolife, a Spanish innovation in female fertility that conquers Boston

The biotechnology company Oxolife, led by the Catalan entrepreneur Agnes Arbat, has established itself as one of the leading participants in Desafia Boston. This innovative Spanish company is revolutionizing the field of female fertility by developing a pioneering drug that improves embryo implantation rates and ovulatory function, especially in women with polycystic ovary syndrome.

After a phase II clinical trial in Europe involving over 400 patients across several countries, the company is preparing to give its project a strategic leap at the international level. Thanks to its participation in Desafia Boston, it is paving the way for a phase III trial that will extend to the United States and Asia-Pacific, two key markets in the field of reproductive health.

Agnes Arbat stresses that the program promoted by ICEX has been a transforming experience both professionally and strategically. As she explains, it allowed her to gain in-depth knowledge of the U.S. biotech ecosystem, establish key contacts with mentors and investors, and better prepare an effective pitch to present her project to pharmaceutical companies and investment funds. In a market as competitive as the U.S., this type of preparation is crucial to access funding and strategic partnerships.

The United States represents the second largest fertility treatment market in the world, making access to this region a priority for Oxolife. The knowledge gained during the program, from regulatory aspects to recruitment and networking dynamics, will allow the company to face its internationalization process with greater strength and establish key relationships in Boston's innovation ecosystem.

In addition, Agnès Arbat's work has recently been recognized with the European Women Innovators Award, an award given by the European Commission that celebrates the impact of leading women in science and technology. This recognition highlights not only Arbat’s achievements but also the growing role of women entrepreneurs in the European biotech sector, reinforcing the importance of supporting female talent in innovation.

Oxolife's case reflects the value of ICEX's support for innovative startups led by women, reinforcing the international projection of Spanish science. "I would definitely recommend other companies to participate in Desafía Boston, as it is a great opportunity. I think it is a unique learning experience and well worth it”, concludes Arbat. From ICEX we encourage other Spanish biotech companies to follow in Oxolife's footsteps and make the most of business growth programs such as Desafía Boston.